Tag: SGN-35
Brentuximab Vedotin Identified as Potentially Transformational in Hodgkin’s lymphoma Treament
Earlier this month, during the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), held in Orlando, Florida from December 5–8,...
Harnessing the Power of Three: Advancing Antibody-Drug Conjugates from Laboratory to...
Antibody-drug conjugates or ADCs are creating much excitement among life science professionals, medical/clinical research scientists and pharmaceutical specialists. At the same time, oncologists and hematologists are eager to welcome new treatment options in the ongoing war against cancer. This article reviews some of the advances made in the development of ADCs.
From the Editors: Welcome to a New Publication – ADC Review/Journal...
Welcome to ADC Review, Journal of Antibody-Drug Conjugates, a new online, peer-reviewed, open-access hybrid publication for those involved in the ongoing--and exciting--development of antibody-drug...
Phase I Trial of Loaded Antibody Establishes Dose, Catalogues Side Effects...
An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38% of patients with relapsed or therapy-resistant Hodgkin lymphoma enrolled in...
Pivotal Trial In Relapsed And Refractory Hodgkin Lymphoma Shows Positive Results...
Results of a pivotal clinical trial with of single-agent brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC) targeted to CD30 shows that the trial drug...
